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In addition to VPAC1 and VPAC2, PAC1 is involved in the pleiotropic action of pituitary adenylate
cyclase activating polypeptide (PACAP) in the CNS. A luciferase reporter assay for the human PAC1
gene (2160/+268) revealed that NGF treatment signiﬁcantly augments the promoter activity of the
PAC1 gene. Moreover, the Sp1 site at 282/273 was shown to be essential for the NGF-augmented
promoter activity of the PAC1 gene. Treatment with U0126, an MEK inhibitor, or Mithramycin A, an
Sp1 inhibitor, signiﬁcantly attenuated promoter activity. These results indicate that activation of
Sp1 by the Ras/MAPK pathway might participate in neuron speciﬁc expression of the PAC1 gene.
Crown Copyright  2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction regulates apoptosis and cell cycle arrest, and p53, a tumor suppres-Pituitary adenylate cyclase activating polypeptide (PACAP) was
ﬁrst isolated from ovine hypothalamus based on its ability to stim-
ulate adenylate cyclase in rat anterior pituitary cells [1]. PACAP has
a crucial role in the central nervous system (CNS) and evidence
suggests that PACAP functions as a hypothalamic hormone, neuro-
trophic factor, neurotransmitter or neuromodulator via three sub-
types of G protein-coupled receptors: PAC1, vasoactive intestinal
polypeptide (VIP) receptors 1 (VPAC1) and 2 (VPAC2) [2]. Whereas
VPAC1 and VPAC2 exhibit similar afﬁnities for PACAP and VIP,
PAC1 is a PACAP speciﬁc receptor that exhibits little afﬁnity for
VIP, and also positively couples to adenylate cyclase and phospho-
lipase C. It is well known that nerve growth factor (NGF) increases
gene expression of PACAP and PAC1 [3,4]. With regard to PACAP,
we previously reported that neuron-restrictive silencer element
(NRSE) was involved in the augmentation of PACAP gene expres-
sion in PC12 cells differentiated by NGF treatment [5]. On the other
hand, the underlying mechanism in the expression of the PAC1
gene is unresolved, although zinc ﬁnger protein (Zac1), whichd by Elsevier B.V. on behalf of Fede
activating polypeptide; VIP,
factor; NRSE, neuron-restric-
1, zinc ﬁnger protein; EMSA,
strictive silencer factor
.jp (A. Miyata).sor gene, have been shown to induce expression of the PAC1 gene
[6]. In this study, we sought to demonstrate the crucial role of Sp1
in the PAC1 gene expression induced by NGF.
2. Materials and methods
2.1. Cell culture
PC12 rat pheochromocytoma cells were obtained from the Insti-
tute of Development, Aging and Cancer, Tohoku University. Cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Sig-
ma–Aldrich, USA) supplemented with 5% fetal bovine serum and
5% horse serum, and treated with 50 ng/ml NGF-b for differentia-
tion as previously described [4].
2.2. Isolation of RNA and real-time PCR
The expression level of PAC1 mRNA was determined by real-
time reverse transcriptase-polymerase chain reaction (RT-PCR).
Total RNA was prepared from PC12 cells as previously described
[4]. Using SYBR Premix Ex Taq™ (Takara Bio, Japan) and the fol-
lowing primers: PAC1 forward primer, 50-CAA GAG GGA AAG ACT
TGT GTT TGA G-30; reverse primer, 50-TTT CCT CTT AAT CTC TGC
CTG TAC CT-30, and GAPDH forward primer, 50-CGG CAA GTT CAA
CGG CAC A-30; reverse primer, 50-AAG ACG CCA GTA GAC TCC
ACG A-30, quantitative real-time PCR was performed for 40 cyclesration of European Biochemical society. All rights reserved.
Table 1
The mutated forms of the Sp1 positions of hPiL-5.
Wild 314 ACCGCGCCCC 305
5mut1 ACgaattCCC
Wild 282 ACCCCGCCCC 273
5mut2 ACgtcgaCCC
Wild 116 GGGGCGGGCA 107
5mut3 GGgaattcCA
Wild +184 GCCGCGGCTG +193
5mut4 gaattcGCTG
Wild +227 AGAACCTCGC +236
5mut5 AGAAgaattc
1732 A. Miura et al. / FEBS Letters 586 (2012) 1731–1735at 95 C for 5 s and 60 C for 31 s with the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, USA).
2.3. Western blotting
Nuclear and cytosolic proteins were extracted from whole cells
by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Ther-
mo, USA) according to manufacturer’s protocol. Each 30-lg protein
was loaded on a 12% polyacrylamide gel for electrophoresis at a0
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Fig. 1. Expression of PAC1 and luciferase activity of various deletion reporter constructs
24 h. (A) mRNA and (B) protein expression of PAC1 was determined by real-time PCR
Schematic representation of the reporter construct including the 2160/+268 region of
numbers are indicated from the adenine of the translation initiation site (ATG) as +1. (D)
the human PAC1 gene in PC12 cells. The PC12 cells were co-transfected for 12 h, before tr
basal control of luciferase activity. The phRL-TK containing a herpes simplex virus thym
control. The relative luciferase activity of the pGL3-promoter was assigned a value of 100
least three separate assays carried out in triplicate. ⁄P < 0.05, ⁄⁄P < 0.001, ⁄⁄⁄P < 0.001 comconstant current of 100 mA/plate for 2 h at room temperature,
and blotted to a polyvinylidene ﬂuoride membrane previously
treated with 100% methanol. After blocking with 5% skimmed milk
dissolved in 20 mM Tris–HCl buffer (pH 7.5) containing 137 mM
NaCl and 0.05% Tween 20, the membrane was incubated with an
antibody against PAC1 (1:5000) (93093-4 was provided by Dr. A.
Arimura), Sp1 (1:200) (1C6, sc-420) (Santa Cruz Biotechnology,
USA) or GAPDH (1:1000) (LV1555185) (Millipore, USA) diluted
with buffer containing 5% skimmed milk, followed by incubation
with an anti-rabbit or anti-mouse IgG antibody (1:1000) conju-
gated with peroxidase. Proteins reactive to those antibodies were
individually detected with the aid of ECL plus (GE Healthcare,
USA) and a Lumino image analyzer (LAS-1000; Fujiﬁlm, Japan).
2.4. Cloning of 50 upstream region 2428 bp of human PAC1 gene
Human PAC1 was cloned using PCR conditions described previ-
ously [4]; brieﬂy, the PAC1F (50-TTG GTG GGC AGT GGG
TAG AGC AGG AT-30) and PAC1R (50-GCC AGA GGA GGG GAT CCG
AGG TC-30) primers (Ensembl Genome Browser: Chromosome7:
31058650–31113403), were used, and PCR was performed for 35
cycles at 94 C for 15 s, 68 C for 2.5 min, and 72 C for 10 min.+
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the human PAC1 gene, including sites for putative transcription factors. Nucleotide
Luciferase activity of various deletion reporter constructs of the 50-ﬂanking region of
eatment with NGF (50 ng/ml) for 24 h. The pGL3-basic reporter vector was used as a
idine kinase (HSV-TK) promoter-driven Renilla luciferase was used as an internal
. The bars represent the mean ± S.E.M. values of relative luciferase activities from at
pared with untreated cells.
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pTA2 vector (Toyobo, Japan), and its sequence was conﬁrmed by
sequencing on an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems).
2.5. Preparation of vector constructs for luciferase reporter assays
The subcloned fragment of the human PAC1 gene was inserted
into pGL3 (Promega, USA) to prepare the reporter vector for PAC1
promoter activity. Human PAC1 genomic fragments spanning
2160 to +268, 1169 to +268, 775 to +268, 607 to +268,
372 to +268, 252 to +268, +23 to +268 and 1169 to +125 were
prepared and designated as hP1L-1, -2, -3, -4, -5, -6, -7 and -8,
respectively. The mutated forms at 5 Sp1 positions of hP1L-5 wereLabeled probe 
Nuclear extracts 
Unlabeled probe 
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Fig. 3. Binding activity of Sp1 with the nuclear extracts of differentiated PC12 cells and e
hP1L-5–2 probe. A 50-fold excess of unlabeled hP1L-5–2 and Sp1 probe was used as a
unlabeled Oct-1 probe was used as non-speciﬁc competitor in lane 5. (B) After treatment
was determined by Western blotting.
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Fig. 2. Effect of a mutation in Sp1-binding sites on luciferase activity stimulated by NGF. (
sites, which are designated as 5mut1, 5mut2, 5mut3, 5mut4 and 5mut5. (B) Luciferase ac
PC12 cells, respectively. ⁄P < 0.05, ⁄⁄⁄P < 0.001 compared with untreated cells.also prepared using the appropriate synthesized primers with the
KOD-Plus-Mutagenesis Kit (Toyobo), and designated as 5mut1,
5mut2, 5mut3, 5mut4 and 5mut5, respectively (Table 1). All DNAs
were prepared using a Qiagen Endofree Maxi kit (Qiagen, Ger-
many) according to manufacturer’s protocol.
2.6. Dual-luciferase reporter assay
PC12 cells were seeded onto 48-well plates at 1  105 cells per
well. The cells were co-transfected with hP1L-1–8 and 5mut1–5
vectors using FuGENE 6 (Roche, USA) according to manufacturer’s
protocol. After treatment with 50 ng/ml NGF-b for 24 h, the cells
were lysed with a passive lysis buffer (Promega) for 15 min at
room temperature. Luciferase activity was quantiﬁed on a Centro 
Sp1
GAPDH
NGF - +
B
xpression level of Sp1 in its nuclear protein. (A) EMSA was performed with labeled
speciﬁc competitor in lanes 3 and 4, respectively. Furthermore, a 50-fold excess of
with NGF for 24 h, PC12 cells were harvested, and nuclear protein expression of Sp1
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A) Schematic representation of the reporter constructs with point mutation of 5 Sp1
tivity of the reporter constructs with mutations in the NGF-treated and non-treated
1734 A. Miura et al. / FEBS Letters 586 (2012) 1731–1735LB960 (Berthold Technologies, Germany) using the Dual-Lucifer-
ase Reporter Assay system (Promega). Fifteen minutes before
NGF treatment, U0126 (Promega), an MEK inhibitor, and Mithra-
mycin A (Wako, Japan), an Sp1 inhibitor, were added to the
medium.
2.7. Electrophoretic mobility shift assay
An electrophoretic mobility shift assay was carried out as previ-
ously described [7]. Brieﬂy, double-stranded oligonucleotide probe
(hP1L-5–2; 50-CGA TCT AAC CCC GCC CCC GGG-30) were synthe-
sized and end-labeled with [c-32P] ATP using T4 polynucleotide
kinase (Promega). An Sp1 double-strand oligonucleotide probe
(50-ATT CGA TCG GGG CGG GGC GAG C-30) was used as a speciﬁc
competitor, and Oct-1 double-strand oligonucleotide probe (50-
TGT CGA ATG CAA ATC ACT AGA A-30) was used as a control. Sub-
sequently, the 32P-labeled oligonucleotide (100,000–500,000 cpm)
was added to the reaction mixture and incubated for 20 min at
room temperature. The resulting mixtures were resolved on 4%
non-denaturing polyacrylamide gel by electrophoresis at 350 V
for 40 min and visualized by autoradiography.0
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Fig. 4. Effects of MEK inhibitor and Sp1 DNA inhibitor on the luciferase activity of
hP1L-5 in the differentiated PC12 cells. After transfection of the reporter vectors, (A)
MEK inhibitor, U0126 (10 lM), (B) Sp1 DNA inhibitor, Mithramycin A (MithA, 50
nM), or DMSO alone for control were added to PC12 cells 15 min prior to NGF
treatment. ⁄P < 0.05, ⁄⁄P < 0.01 compared with untreated cells.3. Results
3.1. The expression of PAC1 mRNA and protein in NGF-treated PC12
cells
Twenty-four hour NGF-treatment increased PAC1 mRNA and
protein expression levels in PC12 cells differentiated by NGF treat-
ment (Fig. 1A and B).
3.2. Characterization of promoter activity in the upstream region of
human PAC1 gene
To determine the promoter activity of the 50-ﬂanking region of
the human PAC1 gene, we performed a luciferase reporter assay
using the reporter constructs. Indeed, using a TFSERCH and TRANS-
FAC, we found that the region at 2160/+268 of the human PAC1
gene contained GATA, Sp1, Oct-1, Zac1, E2F, CCAAT box and NRSE
(Fig. 1C), and that NGF treatment augmented its promoter activity.
Among deletion mutants of the 50-ﬂanking region, hP1L-5, which
contains ﬁve Sp1 sites, CCAAT box, GATA2, 3 and NRSE, exhibited
potent luciferase activity in NGF-treated PC12 cells but not in un-
treated cells (Fig. 1D).
3.3. Sp1 site of 282/273 in hP1L-5 is essential for PAC1 promoter
activity
To examine which Sp1 is involved in NGF-induced PAC1 pro-
moter activity, the mutated forms of ﬁve Sp1 elements of hP1L-5
were prepared (Fig. 2A). In addition to hP1L-5, NGF treatment aug-
mented the promoter activity of 5mut1, 5mut3, 5mut4 and 5mut5,
but not 5mut2 (Fig. 2B). These results suggest that the putative
Sp1-binding elements of 282/273 could be a minimal key re-
gion involved in NGF-speciﬁc promoter activity in PC12 cells.
3.4. Binding activity of the Sp1 of human PAC1 gene with PC12 nuclear
extracts and increased protein level of Sp1
In light of our result that the 282/273 fragment is essential
for potent promoter activity in PC12 cells, we attempted to charac-
terize the transcription factors in the PC12 nuclear extract that
interacted with the 282/273 fragment by electrophoretic
mobility shift assay (EMSA) using the hP1L-5–2 (289/269)
probe (Fig. 3A). In results, with PC12 nuclear extracts, 32P-labeledhP1L-5–2 generated speciﬁc complex (lane 2), which was com-
peted with unlabeled hP1L-5–2 and Sp1 (lanes 3 and 4), but not
with unlabeled Oct-1 (lane 5). In addition, Western blotting analy-
sis demonstrated that Sp1 in nuclear protein fraction was also in-
creased in NGF-treated cells (Fig. 3B).3.5. Effects of MEK inhibitor and Sp1 DNA inhibitor on transcription
activity of PAC1 gene
Using the dual-luciferase reporter assay, we evaluated the inﬂu-
ence of U0126 and Mithramycin A on the promoter activity of
hP1L-5 augmented by NGF stimulation. Treatment with U0126 or
Mithramycin A signiﬁcantly attenuated promoter activity (Fig. 4A
and B). Moreover, treatment with U0126 or Mithramycin A also
inhibited the NGF-induced PC12 cell differentiation (data not
shown).
A. Miura et al. / FEBS Letters 586 (2012) 1731–1735 17354. Discussion
It is well known that PACAP functions as a neurotrophic factor
through PAC1 in the CNS, and that PACAP–PAC1 signaling is also
involved in the neurotrophic action of NGF [2,4,7]. Furthermore,
it has been reported that NGF increase the gene expressions of PA-
CAP and PAC1 in PC12 cells [3,4]. We previously reported that
NRSE is involved in the augmentation of PACAP gene expression
in PC12 cells differentiated by NGF treatment. NRSE is recognized
by a transcription factor known as neuron-restrictive silencer fac-
tor (NRSF), also termed as RE-1 silencing transcription factor [5]. In
contrast, the regulatory mechanism of NGF-mediated PAC1 gene
expression remains unclear. In this study, we used PC12 cells to
evaluate the mechanism of PAC1 gene expression by NGF. hP1L-
5, which contains ﬁve Sp1 sites, CCAAT box, GATA2, 3 and NRSE,
exhibited potent promoter activity induced by NGF in a luciferase
reporter assay. We had ﬁrst treated PC12 cells with Tricostatin A, a
histone deacetylase inhibitor, which indirectly inhibits NRSF-med-
iated gene silencing. However, the expression level of PAC1 mRNA
did not change, which suggests that NRSE might not be involved in
expression of PAC1 gene (data not shown).
Because of reports that Zac1 and p53 induced expression of the
PAC1 receptor in multiple transfected cell lines [6], we compared
the promoter activity of hP1L-4 containing Zac1 with that of
hP1L-5. Since the promoter activity of hP1L-5 without Zac1 was
higher than any other reporter vectors, we concluded that Zac1
does not seem to be involved in NGF-mediated PAC1 gene expres-
sion (data not shown). Incidentally, there is no p53 element in the
50-ﬂanking region of the human PAC1 gene, although p53 may be
involved in expression of mouse PAC1 gene.
On the other hand, we found that treatment with U0126 signiﬁ-
cantly attenuated the promoter activity augmented by NGF; this
agreeswith previous studies that the extracellular Ras/MAPK cascade
is required for effect of NGF-induced PAC1 gene expression [2,10,11].
Furthermore, previous studies have demonstrated that Sp1 is
highly responsive to neurotrophic and growth promoting signals,
since stimulation with NGF increases Sp1 DNA-binding activity
[8,9]. These ﬁndings enabled us to speculate that Sp1 would partic-
ipate in NGF-induced PAC1 gene expression. In fact, the nuclear
protein level of Sp1 was also increased in NGF-treated cells. We
demonstrated that Mithramycin A signiﬁcantly attenuated the pro-
moter activity augmented by NGF. Furthermore, since hP1L-5mut2
did not exhibit increased promoter activity induced by NGF, we
identiﬁed that the Sp1 site at 282/273 was particularly impor-
tant for NGF-speciﬁc expression of the PAC1 gene. We were able to
conﬁrm that probe hP1L-5–2 showed speciﬁc binding with nuclear
extraction of the PC12 cells by EMSA. These ﬁndings corroborate a
previous report that recruitment of Sp1 to the cyclin D1 promoter
is induced by NGF through ERK activation in PC12 cells [12].
In conclusion, we have demonstrated that activation of Sp1
(282/273) via Ras/MAPK pathway might participate in theexpression of PAC1 gene enhanced by NGF. Since there are many
reports with regard to the modulation of PAC1 gene expression
during CNS development and the differentiation of neuronal pro-
genitor cells, it will be interesting to identify how Sp1 is involved
in the regulatory mechanism of PAC1 gene expression during the
development of the brain or CNS.
Acknowledgments
We thank Dr. Hideki Sugawara for his excellent technical assis-
tance and helpful advice. This work was supported by a Grant-in-
Aid for Scientiﬁc Research #21591182 (to A.M.) from the Ministry
of Education, Culture, Sports, Science and Technology of Japan.
References
[1] Miyata, A., Arimura, A., Dahl, R.R., Minamino, N., Uehara, A., Jiang, L., Culler,
M.D. and Coy, D.H. (1989) Isolation of a novel 38 residue-hypothalamic
polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem.
Biophys. Res. Commun. 164, 567–574.
[2] Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O.,
Fournier, A., Chow, B.K., Hashimoto, H., Galas, L. and Vaudry, H. (2009)
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years
after the discovery. Pharmacol. Rev. 61 (3), 283–357.
[3] Hashimoto, H., Hagihara, N., Koga, K., Yamamoto, K., Shintani, N., Tomimoto, S.,
Mori, W., Koyama, Y., Matsuda, T. and Baba, A. (2000) Synergistic induction of
pituitary adenylate cyclase-activating polypeptide (PACAP) gene expression
by nerve growth factor and PACAP in PC12 cells. J. Neurochem. 74 (2), 501–
507.
[4] Tominaga, A., Sugawara, H., Inoue, K. and Miyata, A. (2008) Implication of
pituitary adenylate cyclase-activating polypeptide (PACAP) for
neuroprotection of nicotinic acetylcholine receptor signaling in PC12 cells. J.
Mol. Neurosci. 36 (1–3), 73–78.
[5] Sugawara, H., Inoue, K., Iwata, S., Shimizu, T., Yamada, K., Mori, N. and Miyata,
A. (2004) Neural-restrictive silencers in the regulatory mechanism of pituitary
adenylate cyclase-activating polypeptide gene expression. Regul. Pept. 123 (1–
3), 9–14.
[6] Hoffmann, A., Ciani, E., Houssami, S., Brabet, P., Journot, L. and Spengler, D.
(1998) Induction of type I PACAP receptor expression by the new zinc ﬁnger
protein Zac1and p53. Ann. N. Y. Acad. Sci. 11 (865), 49–58.
[7] Rajagopal, R., Chen, Z.Y., Lee, F.S. and Chao, M.V. (2004) Transactivation of Trk
neurotrophin receptors by G-protein-coupled receptor ligands occurs on
intracellular membranes. J. Neurosci. 24, 6650–6658.
[8] Saffer, J.D., Jackson, S.P. and Annarella, M.B. (1991) Developmental expression
of Sp1 in the mouse. Mol. Cell. Biol. 11, 2189–2199.
[9] Crumpton, T., Atkins, D.S., Zawia, N.H. and Barone Jr., S. (2001) Lead exposure
in pheochromocytoma (PC12) cells alters neural differentiation and Sp1 DNA-
binding. Neurotoxicology 22, 49–62.
[10] Vaudry, D., Stork, P.J., Lazarovici, P. and Eiden, L.E. (2002) Signaling pathways
for PC12 cell differentiation: making the right connections. Science 296
(5573), 1648–1649.
[11] Jamen, F., Bouschet, T., Laden, J.C., Bockaert, J. and Brabet, P. (2002) Up-
regulation of the PACAP type-1 receptor (PAC1) promoter by neurotrophins in
rat PC12 cells and cerebellar granule cells via the Ras/mitogen-activated
protein kinase cascade. J. Neurochem. 82, 1199–1207.
[12] Marampon, F., Casimiro, M.C., Fu, M., Powell, M.J., Popov, V.M., Lindsay, J., Zani,
B.M., Ciccarelli, C., Watanabe, G., Lee, R.J. and Pestell, R.G. (2008) Nerve Growth
factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular
signal-regulated kinase pathway requires cooperative interactions between
Sp1 and nuclear factor-kappaB. Mol. Biol. Cell 19 (6), 2566–2578.
